Lectins use for receive and study of glioma C6 cells with stem cells properties

Authors

  • Nikolay Lisianyi Romodanov Neurosurgery Institute, Kiev, Ukraine
  • Irina Gnedkova Neuroimmunology Department, Romodanov Neurosurgery Institute, Kiev, Ukraine
  • Diana Stanetskaya Neuroimmunology Department, Romodanov Neurosurgery Institute, Kiev, Ukraine
  • Volodymyr Rozumenko Intracerebral Tumors Department, Romodanov Neurosurgery Institute, Kiev, Ukraine
  • Alexandr Glavatskiy Intracerebral Tumors Department, Romodanov Neurosurgery Institute, Kiev, Ukraine
  • Anna Shmeleva Neuropathomorphology Department, Romodanov Neurosurgery Institute, Kiev, Ukraine
  • Tatyana Malysheva Neuropathomorphology Department, Romodanov Neurosurgery Institute, Kiev, Ukraine
  • Oksana Chernenko Neuropathomorphology Department, Romodanov Neurosurgery Institute, Kiev, Ukraine
  • Mаrianna Gnedkova Department of Anesthesiology and Intensive Care #2, Romodanov Neurosurgery Institute, Kiev, Ukraine

DOI:

https://doi.org/10.25305/unj.45289

Keywords:

глиома С6, стволовые клетки опухоли, лектины

Abstract

The purpose — to enrich suspension of glioma C6 cells in rats with stem tumor stem cells using lectins sorbed on plastic.

Materials and methods. Lectins of beans (Phaseolus vulgaris — PHA), concanavalin (ConA), peanuts (peanut agglutinin — PNA), mistletoe (Mil), labrum anagyroides agglutinin (LABA), soybean (SBA) were used to separate glioma C6 cells.

Glioma C6 cells were cultivated with sorbed lectins for 24 h and were injected into the brain of the rats.

Results. Tumorogenic activity was significantly higher in fractions of cells adhered to plastic with adsorbed lectins PHA, ConA, PNA, LABA and SBA, that was an indirect evidence of these fractions enriched by tumor stem cells. Lectin Mil exert an antitumor effect that contributed to rats’ lifetime increasing.

Conclusions. The results of the study indicate the possibility of tumor cells division using lectins.

Author Biography

Nikolay Lisianyi, Romodanov Neurosurgery Institute, Kiev

Neuroimmunology Department

References

Brescia P, Richichi C, Pelicci G. Current Strategies for Identification of Glioma Stem Cells: Adequate or Unsatisfactory? Journal of Oncology. 2012;2012:1-10. CrossRef

Dey M, Ulasov I, Tyler M, Sonabend A, Lesniak M. Cancer Stem Cells: The Final Frontier for Glioma Virotherapy. Stem Cell Reviews and Reports. 2010;7(1):119-129. CrossRef

Dodla M, Young A, Venable A et al. Differing Lectin Binding Profiles among Human Embryonic Stem Cells and Derivatives Aid in the Isolation of Neural Progenitor Cells. PLoS ONE. 2011;6(8):e23266. CrossRef

Christensen K, Schrøder H, Kristensen B. CD133 identifies perivascular niches in grade II–IV astrocytomas. Journal of Neuro-Oncology. 2008;90(2):157-170. CrossRef

Schraen-Maschke S. Role of oligomannosidic N-glycans in the proliferation, adhesion and signalling of C6 glioblastoma cells. Biochimie. 2003;85(1-2):219-229. CrossRef

Angelastro J, Lame M. Overexpression of CD133 Promotes Drug Resistance in C6 Glioma Cells. Molecular Cancer Research. 2010;8(8):1105-1115. CrossRef

Tucker-Burden C, Chappa P, Krishnamoorthy M et al. Lectins Identify Glycan Biomarkers on Glioblastoma-Derived Cancer Stem Cells. Stem Cells and Development. 2012;21(13):2374-2386. CrossRef

Dai L, Liu Y, He J et al. Differential profiling studies of N-linked glycoproteins in glioblastoma cancer stem cells upon treatment with γ-secretase inhibitor. PROTEOMICS. 2011;11(20):4021-4028. CrossRef

Chen R, Nishimura M, Bumbaca S et al. A Hierarchy of Self-Renewing Tumor-Initiating Cell Types in Glioblastoma. Cancer Cell. 2010;17(4):362-375. CrossRef

Wang Y, Nakagawa M, Garitaonandia I et al. Specific lectin biomarkers for isolation of human pluripotent stem cells identified through array-based glycomic analysis. Cell Res. 2011;21(11):1551-1563. CrossRef

Son M, Woolard K, Nam D, Lee J, Fine H. SSEA-1 Is an Enrichment Marker for Tumor-Initiating Cells in Human Glioblastoma. Cell Stem Cell. 2009;4(5):440-452. CrossRef

Venable A, Mitalipova M, Lyons I, Jones K, Shin S, Pierce M, Stice S. Lectin binding profiles of SSEA-4 enriched, pluripotent human embryonic stem cell surfaces. BMC Dev Biol. 2005;5(1):15. CrossRef

Lou Y, Wang P, Yeh S et al. Stage-specific embryonic antigen-4 as a potential therapeutic target in glioblastoma multiforme and other cancers. Proceedings of the National Academy of Sciences. 2014;111(7):2482-2487. CrossRef

Butakov A, Oganezov V, Pinegin P. Spektrofotometricheskoye opredeleniye adgezivnoy sposobnosti polimorfoyadernykh leykotsitov perifericheskoy krovi. Immunologiya. 2015;5:71–73. Russian.

Antonyuk V. Lektyny ta yikh syrovynni dzherela. Lviv: Kvart; 2005:554. Ukrainian.

Nduom E, Hadjipanayis C, Van Meir E. Glioblastoma Cancer Stem-Like Cells: Implications for Pathogenesis and Treatment. The Cancer Journal. 2012;18(1):100-106. CrossRef

Downloads

Published

2015-06-27

How to Cite

Lisianyi, N., Gnedkova, I., Stanetskaya, D., Rozumenko, V., Glavatskiy, A., Shmeleva, A., Malysheva, T., Chernenko, O., & Gnedkova, M. (2015). Lectins use for receive and study of glioma C6 cells with stem cells properties. Ukrainian Neurosurgical Journal, (2), 11–16. https://doi.org/10.25305/unj.45289

Issue

No. 2 (2015)

Section

Original articles

License

Copyright (c) 2015 Nikolay Lisianyi, Irina Gnedkova, Diana Stanetskaya, Volodymyr Rozumenko, Alexandr Glavatskiy, Anna Shmeleva, Tatyana Malysheva, Oksana Chernenko, Mаrianna Gnedkova

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Ukrainian Neurosurgical Journal abides by the  CREATIVE COMMONS copyright rights and permissions for open access journals.

Authors, who are published in this Journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the Journal under the terms of Creative Commons Attribution License, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this Journal.

2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form of which it has been published by the Journal (for example, to upload the work to the online storage of the Journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this Journal is included.